# Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma

> **NCT05527795** · — · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 1000 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **OTHER:** Frequency and duration of response to adjuvant immunotherapy according to clinical features
- **OTHER:** Frequency of each type of relapse (i. e. local, distant, unique or multiple) to adjuvant therapy according to clinical features
- **OTHER:** Duration of relapse-free survival according to clinical features
- **OTHER:** Duration of overall survival according to clinical features
- **OTHER:** Overall response rate
- **OTHER:** Frequency of adverse events according to clinical features

## Key facts

- **NCT ID:** NCT05527795
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-01
- **Primary completion:** 2029-01-01
- **Final completion:** 2039-01-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2022-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05527795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05527795, "Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05527795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*